Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | AR | P10275 | 2/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4081611 | 0.92 | MAPT (0.59) | CETPMAPTGAAALDH1A1NPSR1 | |
| SCHEMBL347552 | 0.90 | PTGDR2 (0.62) | CETPMAPTGAAALDH1A1NPSR1 | |
| SCHEMBL4085482 | 0.86 | AR (0.65) | CETPMAPTALDH1A1NPSR1HTT | |
| SCHEMBL348313 | 0.86 | GFER (0.50) | CETPMAPTGAAALDH1A1NPSR1 | |
| Trifluoroacetic Acid SCHEMBL4081620 | 0.83 | GFER (0.46) | CETPMAPTGAAALDH1A1NPSR1 | |
| SCHEMBL4661535 | 0.83 | NPSR1 (0.46) | CETPMAPTALDH1A1NPSR1HTT | |
| SCHEMBL347930 | 0.83 | ALDH1A1 (0.63) | CETPMAPTGAAALDH1A1NPSR1 | |
| SCHEMBL4093773 | 0.81 | ALDH1A1 (0.61) | CETPMAPTGAAALDH1A1NPSR1 | |
| SCHEMBL4630926 | 0.81 | DHODH (0.54) | CETPMAPTGAAALDH1A1NPSR1 | |
| SCHEMBL4081626 | 0.80 | CETP (0.43) | CETPMAPTGAAALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160199386-A1 | METHODS OF TREATING THYROID EYE DISEASE | UNIVERSITY OF ROCHESTER (US) | 2016-07-14 | — | — | US | claimed |
| US-20120015001-A1 | METHODS OF TREATING THYROID EYE DISEASE | UNIVERSITY OF ROCHESTER (US) | 2012-01-19 | — | — | US | claimed |
| US-9750749-B2 | Methods of treating thyroid eye disease | UNIVERSITY OF ROCHESTER (US) | 2017-09-05 | — | — | US | disclosed |
| US-20160199386-A1 | METHODS OF TREATING THYROID EYE DISEASE | UNIVERSITY OF ROCHESTER (US) | 2016-07-14 | — | — | US | disclosed |
| US-9320723-B2 | Methods of treating thyroid eye disease | UNIVERSITY OF ROCHESTER (US) | 2016-04-26 | — | — | US | disclosed |
| US-20120015001-A1 | METHODS OF TREATING THYROID EYE DISEASE | UNIVERSITY OF ROCHESTER (US) | 2012-01-19 | — | — | US | disclosed |
| US-20090221604-A1 | Thiazole Compounds and Their Use as PGD2 Antagonists | ARGENTA DISCOVERY LIMITED (GB) | 2009-09-03 | — | — | US | disclosed |
| US-20090221604-A1 | Thiazole Compounds and Their Use as PGD2 Antagonists | ARGENTA DISCOVERY LIMITED (GB) | 2009-09-03 | — | — | US | disclosed |
| US-20090221604-A1 | Thiazole Compounds and Their Use as PGD2 Antagonists | ARGENTA DISCOVERY LIMITED (GB) | 2009-09-03 | — | — | US | disclosed |
| EP-1922312-A1 | THIAZOLE COMPOUNDS AND THEIR USE AS PGD2 ANTAGONISTS | Argenta Discovery Limited (GB) | 2008-05-21 | — | — | EP | disclosed |
| WO-2007028999-A1 | THIAZOLE COMPOUNDS AND THEIR USE AS PGD2 ANTAGONISTS | ARGENTA DISCOVERY LIMITED (GB) | 2007-03-15 | — | — | WO | disclosed |
| WO-2007028999-A1 | THIAZOLE COMPOUNDS AND THEIR USE AS PGD2 ANTAGONISTS | ARGENTA DISCOVERY LIMITED (GB) | 2007-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221604-A1 | Thiazole Compounds and Their Use as PGD2 Antagonists | PTGDR2, PTGDR, PTGER2 | CETP 4678/4885MAPT 4289/4885GAA 3881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.